EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-world acute myeloid leukemia outcomes during a decade of molecular diagnostic expansion and azacitidine plus venetoclax adoption in Thailand: A single-center implementation cohort

Thanawat Rattanathammethee, Noppamas Panyasit, Piangrawee Niprapan, Sirichai Srichairatanakool, Teerachat Punnachet, Nonthakorn Hantrakun, Pokpong Piriyakhuntorn, Sasinee Hantrakool, Chatree Chai-Adisaksopha, Adisak Tantiworawit, Lalita Norasetthada, Ekarat Rattarittamrong

Therapeutic Advances in Hematology · 2026-10 · 17

DOI: 10.1177/20406207261503620 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Hematology, online erschienen am 30.10.2026. Verfasst von Thanawat Rattanathammethee und 11 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chiang Mai University Fundamental Fund 2026, Ministry of Higher Education, Science, Research and Innovation, Thailand.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Expanded molecular diagnostics and introduction of azacitidine plus venetoclax have reshaped acute myeloid leukemia (AML) management. However, real-world data on these impacts in Southeast Asia remain limited.

Objectives

To evaluate clinical outcomes across two implementation eras defined by expanded molecular testing and adopting of azacitidine plus venetoclax.

Design

Retrospective single-center cohort study.

Methods

We included adults with newly diagnosed AML, comparing early (2016-2020) and later (2021-2025) eras. The primary endpoint was the adjusted between-era difference in 24-month restricted mean survival time (RMST) for overall survival (OS). Secondary approaches included propensity score matching (PSM) to adjust for baseline imbalances and a 6-month landmark analysis to evaluate allogeneic stem cell transplantation (alloSCT) outcomes without immortal time bias.

Results

Among 285 patients, 228 received AML-directed therapy (early n=107; later n=121). Later-era patients were significantly older and more frequently classified as ELN adverse risk, coinciding next-generation sequencing implementation (22.3%). Adjusted 24-month RMST for OS did not differ between eras (difference -0.06 months; 95% CI -2.41 to 2.27; p = 0.956). To control for referral bias, a 1:1 PSM yielded 84 well-balanced pairs (n=168). Within this matched cohort, median OS (15.4 vs. 14.7 months; HR 1.02; p = 0.908) and relapse-free survival remained comparable between eras. In the 6-month landmark analysis of the PSM subset, alloSCT demonstrated a clinical trend toward reduced mortality (adjusted HR 0.69, 95% CI 0.34 to 1.38).

Conclusion

Despite major shifts in treatment patterns, no improvement in adjusted short-term survival was observed at the population level. Notably, the higher proportion of adverse risk patients in the later era likely reflects both enhanced molecular ascertainment and changes in referral patterns, rather than a pure biological shift alone. Expanding transplant access and comprehensive molecularly guided therapy remain key priorities.

Förderung

  • Chiang Mai University Fundamental Fund 2026
  • Ministry of Higher Education, Science, Research and Innovation, Thailand

Zitieren

APA

Rattanathammethee, T., Panyasit, N., Niprapan, P., Srichairatanakool, S., Punnachet, T., Hantrakun, N., Piriyakhuntorn, P., Hantrakool, S., Chai-Adisaksopha, C., Tantiworawit, A., Norasetthada, L., & Rattarittamrong, E. (2026). Real-world acute myeloid leukemia outcomes during a decade of molecular diagnostic expansion and azacitidine plus venetoclax adoption in Thailand: A single-center implementation cohort. Therapeutic Advances in Hematology, 17. https://doi.org/10.1177/20406207261503620

Vancouver

Rattanathammethee T, Panyasit N, Niprapan P, Srichairatanakool S, Punnachet T, Hantrakun N, et al. Real-world acute myeloid leukemia outcomes during a decade of molecular diagnostic expansion and azacitidine plus venetoclax adoption in Thailand: A single-center implementation cohort. Therapeutic Advances in Hematology. 2026;17. doi:10.1177/20406207261503620

BibTeX
@article{Rattanathammethee2026,
  author = {Rattanathammethee, Thanawat and Panyasit, Noppamas and Niprapan, Piangrawee and Srichairatanakool, Sirichai and Punnachet, Teerachat and Hantrakun, Nonthakorn and Piriyakhuntorn, Pokpong and Hantrakool, Sasinee and Chai-Adisaksopha, Chatree and Tantiworawit, Adisak and Norasetthada, Lalita and Rattarittamrong, Ekarat},
  title = {Real-world acute myeloid leukemia outcomes during a decade of molecular diagnostic expansion and azacitidine plus venetoclax adoption in Thailand: A single-center implementation cohort},
  journal = {Therapeutic Advances in Hematology},
  year = {2026},
  volume = {17},
  doi = {10.1177/20406207261503620}
}
Kostenlos starten →